Last Price
102.63
Today's Change
-2.12 (2.02%)
Day's Change
101.16 - 106.08
Trading Volume
532,822
Market Cap
6 Billion
Shares Outstanding
64 Million
Avg Volume
421,866
Avg Price (50 Days)
80.45
Avg Price (200 Days)
76.21
PE Ratio
-36.78
EPS
-2.79
Earnings Announcement
07-Nov-2024
Previous Close
104.75
Open
105.07
Day's Range
101.16 - 106.0824
Year Range
41.16 - 113.51
Trading Volume
532,822
1 Day Change
-2.02%
5 Day Change
24.46%
1 Month Change
43.42%
3 Month Change
31.41%
6 Month Change
31.39%
Ytd Change
34.86%
1 Year Change
130.73%
3 Year Change
187.48%
5 Year Change
447.36%
10 Year Change
447.36%
Max Change
447.36%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.